Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Veracyte

Request full access

Diagnostics for cancer

San Francisco, United StatesFounded 2008Biotech & Life Sciences

At a glance

Status
Listed
Listing
IPO 2013

Veracyte in the San Francisco ecosystem

Live from Dealroom

The Veracyte office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later6 investors entered at this stage

Employees mapped 731 incl. 14 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 7 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia 7 alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$38M

34 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Investments and acquisitions

Disclosed deals where Veracyte was the backer or acquirer, 2014–2024. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

4 deals across Veracyte's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        Veracyte's portfolio, mapped.

        Stage
        Period
        4 of 4 deals

        See Veracyte on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.